Susan Domchek

CURE® to Host Educated Patient Summit at Miami Breast Cancer Conference®

Retrieved on: 
Thursday, January 16, 2020
Other Health, Research, MEN, Family, Consumer, Hospitals, Science, Women, Nursing, Seniors, Other Science, Health, Health, Cancer, Susan G. Komen for the Cure, Triple Negative Breast Cancer Foundation, Breast cancer, Breast cancer awareness, Susan Domchek

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients, will host several patient-focused sessions on breast cancer Saturday, March 7, at Fontainebleau Miami Beach in Florida during the Physicians Education Resource 36th Annual Miami Breast Cancer Conference.

Key Points: 
  • CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients, will host several patient-focused sessions on breast cancer Saturday, March 7, at Fontainebleau Miami Beach in Florida during the Physicians Education Resource 36th Annual Miami Breast Cancer Conference.
  • We are so honored to be able to make a direct impact on the lives of breast cancer patients by hosting our second patient-focused summit held in tandem with the Miami Breast Cancer Conference, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of CURE magazine.
  • This one-day breast cancer program will represent all stages of disease and demographics of patients with breast cancer, as well as their caregivers and advocates.
  • CURE is partnering with METAvivor , Susan G. Komen Miami/Fort Lauderdale , Susan G. Komen Florida and Triple Negative Breast Cancer Foundation to present CURE's Educated Patient Summit on breast cancer.

Susan G. Komen® Study Confirms Treatment Options for HER2-negative Patients With BRCA1/2 Mutations

Retrieved on: 
Friday, December 13, 2019
Oncology, Health, Consumer, Women, Clinical trials, Research, Science, Cancer, Health, Hereditary cancers, Branches of biology, Tumor markers, Tumor suppressor genes, Susan G. Komen for the Cure, BRCA1, Breast cancer, BRCA mutation, BRCA, Susan Domchek

The Komen-funded INFORM trial led by Dr. Nadine Tung shows that HER2-negative patients with a BRCA1/2 gene mutation have multiple effective treatment options.

Key Points: 
  • The Komen-funded INFORM trial led by Dr. Nadine Tung shows that HER2-negative patients with a BRCA1/2 gene mutation have multiple effective treatment options.
  • The INFORM clinical trial was the first prospective study, or a study that evaluates treatment moving forward, to actually test this idea.
  • Victoria Wolodzko, senior vice president of Mission at Susan G. Komen, added, Patients with BRCA mutations face many challenges, especially those in rural or underserved areas.
  • Susan G. Komen is the worlds leading nonprofit breast cancer organization, working to save lives and end breast cancer forever.